Omvoh and Humira take different mechanistic approaches to moderate-to-severe ulcerative colitis. Humira is the established anti-TNF with more than a decade of UC experience. Omvoh is an IL-23 p19-selective biologic approved for UC in October 2023 based on the LUCENT-1 and LUCENT-2 trials, making it the first drug in its class approved for UC. Patients choosing between these drugs weigh mechanism, safety, and long-term administration convenience. This guide walks through the omvoh vs humira ulcerative colitis decision.
IL-23 p19 vs Anti-TNF Mechanism
Humira (adalimumab) is a fully human monoclonal antibody that binds TNF-alpha and reduces inflammation throughout the body and in the colon. Omvoh (mirikizumab) binds the p19 subunit of interleukin-23, selectively blocking IL-23 signaling. IL-23 is central to Th17-driven inflammation in UC. The mirikizumab vs adalimumab UC distinction shapes efficacy timing, safety profile, and long-term convenience. Humira's broader TNF blockade produces faster systemic anti-inflammatory effects and covers extraintestinal manifestations. Omvoh's narrower IL-23 targeting produces strong efficacy with a cleaner safety profile and preserves IL-12 for immune surveillance.
LUCENT-1 and LUCENT-2: Omvoh UC Evidence
LUCENT-1 was the pivotal phase 3 induction trial of mirikizumab in UC, randomizing biologic-naive and biologic-experienced UC patients to IV mirikizumab induction or placebo. At week 12, 24.2% of mirikizumab patients achieved clinical remission compared with 13.3% on placebo, with endoscopic remission, symptomatic remission, and bowel urgency improvement also significantly better. LUCENT-2, the maintenance trial, randomized week-12 responders to continue SC mirikizumab or switch to placebo, with 49.9% of mirikizumab patients in clinical remission at week 40 versus 25.1% on placebo. Humira's UC efficacy rests on ULTRA-1 and ULTRA-2, which established modest but meaningful benefit over placebo in biologic-naive UC patients.
Efficacy Comparison
No head-to-head trial has compared Omvoh with Humira in UC. Indirect comparisons suggest Omvoh produces similar or potentially higher clinical remission rates than Humira in biologic-naive UC patients. The VARSITY head-to-head trial showed Humira underperforming compared with gut-selective Entyvio, which has broader implications for how anti-TNFs compare with newer mechanism classes. For anti-TNF experienced UC patients, Omvoh's p19 selectivity offers a meaningful mechanism switch. LUCENT included biologic-experienced patients and showed response rates consistent with a class-switch strategy.
Onset of Action and Urgency Improvement
Humira tends to produce early symptom improvement within the first few weeks of induction. Omvoh's UC onset produces meaningful response by week 12 based on LUCENT-1. A distinctive feature of Omvoh's data is bowel urgency improvement, a patient-reported outcome often undertreated in UC. LUCENT showed significant improvement in urgency numerical rating scale scores, which matters to patients whose daily life is disrupted by sudden urgency episodes. For UC patients with severe, active symptoms who need rapid control, Humira's faster onset is often preferred. For patients prioritizing urgency relief or long-term safety, Omvoh's trajectory and data profile are often attractive.
Safety Profiles
Humira carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Omvoh's UC safety data from LUCENT has been favorable, with lower rates of serious infection than anti-TNFs and a safety profile consistent with other IL-23 p19 biologics. For omvoh vs humira side effects, UC patients with infection concerns, cancer history, or extraintestinal risk factors often find Omvoh's narrower mechanism more reassuring. Both drugs require TB and hepatitis B screening before starting, and both can be used as monotherapy.
Administration and Dosing
Humira for UC is a subcutaneous injection throughout. Induction is 160 mg on day 1 and 80 mg on day 15, followed by 40 mg every other week, per AbbVie's prescribing information. Omvoh uses IV induction at 300 mg every 4 weeks for three doses (weeks 0, 4, and 8), followed by subcutaneous maintenance at 200 mg every 4 weeks, per Lilly's Omvoh prescribing information. For UC patients comparing long-term dosing, Humira's every-other-week SC frequency is more frequent than Omvoh's every-4-week SC maintenance. Humira has fully SC induction. Omvoh requires IV induction before transitioning to SC maintenance.
Cost and Access
Humira faces extensive biosimilar competition. Multiple adalimumab biosimilars are designated interchangeable with Humira, including Amjevita, Cyltezo, Hyrimoz, Abrilada, Hulio, Simlandi, and Yuflyma. Many pharmacy benefit managers prefer biosimilar adalimumab. Omvoh has no biosimilar and is priced as a branded biologic. For UC patients where insurance strongly favors a low-cost adalimumab biosimilar, Humira (or its biosimilar) may be the most accessible option. For patients whose plans cover Omvoh and prioritize the IL-23 mechanism, urgency outcomes, or less frequent SC dosing, manufacturer copay assistance programs can help bridge cost gaps.
Choosing With Your GI
For a UC patient deciding between Omvoh and Humira, Humira tends to win on speed of onset, biosimilar cost savings, coverage of extraintestinal manifestations, and all-SC administration. Omvoh tends to win on long-term safety, less frequent SC maintenance, and a distinctive urgency-focused efficacy profile from LUCENT. Ask your GI how response will be measured after induction, what to do if symptoms persist, and how your insurance handles adalimumab biosimilars versus branded IL-23 biologics. A log of stool frequency, urgency episodes, blood, and any new extraintestinal symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.